Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

SSTR2 Protein-VLP (AA 1-369)

SSTR2 Origin: Human Host: HEK-293 Cells VLP > 95 % as determined by HPLC ELISA, Imm, Func, SPR Active
Catalog No. ABIN7448172
  • Target See all SSTR2 Proteins
    SSTR2 (Somatostatin Receptor 2 (SSTR2))
    Protein Type
    VLP
    Biological Activity
    Active
    Protein Characteristics
    AA 1-369
    Origin
    • 10
    • 1
    Human
    Source
    • 5
    • 3
    • 2
    • 1
    HEK-293 Cells
    Application
    ELISA, Immunogen (Imm), Functional Studies (Func), Surface Plasmon Resonance (SPR)
    Purpose
    Human SSTR2 Protein-VLP
    Sequence
    Met1-Ile369
    Characteristics
    Recombinant Human SSTR2 Protein-VLP is expressed from HEK293.It contains Met1-Ile369.
    Purity
    > 95 % as determined by HPLC
    Sterility
    0.22 μm filtered
    Endotoxin Level
    Less than 1EU per μg by the LAL method.
    Biological Activity Comment
    Immobilized Human SSTR2 VLP at 5μg/ml on the plate (100μl/Well). Dose response curve for Anti-SSTR2 Antibody, hFc Tag with the EC50 of 32.8ng/ml determined by ELISA.
  • Application Notes
    • Antibody Discovery: Immunization, Screening, Functional Characterization
    • Affinity determination: ELISA, SPR
    • In vivo pharmacokinetic analysis
    • CMC method development
    • CAR-T Positive Rate Detection
    • Blood sample determination: ELISA
    Comment

    Virus-like particles (VLPs) are formed from the outer capsid protein of a virus and are tiny nanoparticles formed by the automatic assembly of one or more capsid proteins. VLPs do not contain viral infectious genomes, so they are relatively safe during production operations. The SAMS™ protein engineering platform has been used to express a series of biotinylated, non-biotinylated, and fluorescently-labeled VLP-displayed antigens. They are suitable for SPR, ELISA, CAR-T positive rate detection, and other experimental scenarios.

    Virus-Like Particles (VLPs) are highly immunogenic, meaning that they can elicit a strong immune response in the host. VLPs are recognized by the immune system and are taken up by antigen-presenting cells (APCs) such as dendritic cells. Once taken up by APCs, VLPs are processed and presented to T cells, which can trigger the activation of B cells to produce antibodies against the displayed antigen. Because VLPs resemble the structure and composition of native viruses, they are highly effective at inducing both humoral and cellular immune responses.

    Generally, VLPs range in size from approximately 20 to 200 nanometers (nm). Compared to a cell-based immunization approach, their smaller size can optimize the immune response to target the specific antigen displayed on the surface of the engineered VLPs.

    Restrictions
    For Research Use only
  • Format
    Liquid
    Buffer
    Supplied as 0.22μm filtered solution in PBS ( pH 7.4). Notice: If you need it for immunization, Do Not use any adjuvant.
    Storage
    -80 °C
    Storage Comment
    Valid for 12 months from date of receipt when stored at -80°C., Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
    Expiry Date
    12 months
  • Target
    SSTR2 (Somatostatin Receptor 2 (SSTR2))
    Alternative Name
    SSTR2 (SSTR2 Products)
    Synonyms
    Smstr2 Protein, SSTR-2 Protein, Smstr-2 Protein, sst2 Protein, SS2R Protein, SSTR2 Protein, MGC80373 Protein, somatostatin receptor 2 Protein, somatostatin receptor 2 L homeolog Protein, SSTR2 Protein, Sstr2 Protein, sstr2.L Protein
    Background
    Somatostatin receptor (SSTR) 2, widely expressed in meningioma, is a G-protein-coupled receptor and can be activated by somatostatin or its synthetic analogs. SSTR2 is therefore extensively studied as a marker and target for the diagnosis and treatment of meningioma.
    Molecular Weight
    42.7 kDa.
You are here: